MAIN AGENDA

DOWNLOAD BROCHURE

Singapore, 18 - 20 March 2019

Schedule

Create your personal agenda –check the favourite icon

Mar 1908:50
Conference pass
Mar 1909:00
Conference pass

Going global and keeping it local: Is biotech innovation sustainable in Asia?

Keynotes
In this keynote presentation, Sir David Lane, one of the key scientists credited on the discovery of cancer gene p53, a gene which mutation cause near 50% of all human cancer, will share his view on how biomedical sciences have developed in Singapore, Japan and the remaining APAC region, and prospects for Asian biotech and pharma industry.
Mar 1909:20
Conference pass

Looking east: Integrating Asia into the global era of innovative medicine

Keynotes
Mar 1909:40
Conference pass

Pharma Trends: Women health as the next focus

Keynotes
By 2023, it is estimated that the women’s health market will be worth $37.4 billion. But despite this impressive growth, across the world there are still significant unmet needs in the space. In this panel discussion, we will explore the significant opportunities in the women’s health market, from drug discovery and development to effective clinical trials and ensuring access to treatment, including both strategy development and technology advances.
Evelyn Pang, Manager, L.E.K. ConsultingSingapore
Marcel Van Duin, VP Research, Therapeutic Area Head, Reproductive Medicine & Women's Health, Ferring PharmaceuticalsUnited States
Mar 1910:10
Conference pass

Driving innovation forward: The Johnson & Johnson perspective

Keynotes
Fostering innovation is a big challenge, so what’s the recipe for success? In this session, learn about how Johnson & Johnson Innovation is helping to accelerate life sciences innovation and how its Asia Pacific team is creating new opportunities for emerging biotech and pharma businesses. Nilesh will share insights into Johnson & Johnson’s unique model for addressing the major challenges in local innovation ecosystems, and how new collaborations are helping transform the trajectory of human health.
Mar 1911:15
Conference pass

Chair's opening remarks

Immunotherapy
Mar 1911:15
Conference pass
Mar 1911:15
Conference pass

Chair's opening remarks

Biotech Inve$t
Mar 1911:20
Conference pass

What’s next after anti-PD1/PD-11 Immune Checkpoint Inhibitors?

Immunotherapy
Mar 1911:20
Conference pass

A provider’s perspective in ensuring clinical trial quality

Clinical trials
  • Suggestions in promoting collaboration required between pharma, CRO and providers to promote trial efficiency
  • Educational efforts and processes preparation required to ensure trials quality
  • Case study sharing
Mar 1911:20
Conference pass

Stakeholder mapping, acquisition & activation strategies

Access
Mar 1911:20
Conference pass

The transformation of the Bio pharma industry. Top growth opportunities for 2025

Pharma 4.0
Mar 1911:20
Conference pass

Medtech, Diagnostics, Wearables- What are the next trends in biotech investment landscape?

Biotech Inve$t
Dean Ho, Co-Founder, KYAN TherapeuticsUnited States
Mario Gattino, Chief Executive Officer, RespiriAustralia
Ashish Patel, Head Of Research, Investment Manager, Mercia TechnologiesUnited Kingdom
Mar 1911:40
Conference pass

How do domestic companies gain edge in the competitive global immunotherapy landscape?

Immunotherapy
Mar 1911:40
Conference pass

Clinical research quality by design

Clinical trials
  • Quality data in clinical development
  • Data integrity in clinical trials
  • Quality risk management
Mar 1911:40
Conference pass

Collaborative efforts in building the common ground for better accessibility and treatment

Access
  • Key actions to bridge the gaps between stakeholders to provide for population in need
  • Models in helping advocacy group to coordinate for better access to treatment
  • Building the common ground in promoting better collaboration between advocacy groups, government, pharma and other stakeholders
Moderator: Chris Hardesty, Director, KPMG Singapore Life SciencesSingapore
Nadia Suttikulpanich, Head Of Fuchsia Innovation Center For Muang Thai Life Assurance, Muang Thai Life Assurance Public CompanyThailand
Mar 1911:40
Conference pass

Increasing transparency and knowledge-sharing efficiency with blockchain

Pharma 4.0
Mar 1912:00
Conference pass

The next big trend in Asia immunotherapy landscape: A case study in China

Immunotherapy
Mar 1912:00
Conference pass

Process and Frequency Findings of GCP Inspection: EMA and US FDA

Clinical trials
This presentation shares insights from Asia, EMA and FDA inspections with case studies on biosimilar trials. It will also discuss the influence of the nature of company on site monitoring activities
Hyejin Shin, Director, Group Leader, Clinical Qa, Samsung BioepisRepublic Of Korea
Mar 1912:00
Conference pass

AI- enhanced drug development platforms

Pharma 4.0
Mar 1912:10
Conference pass

Biotech Pitch

Biotech Inve$t
10 minutes per company
Jeong Beom Kim, CEO, SuPine TherapeuticsRepublic Of Korea
Ken Taylor, Chief Executive Officer, Living Cell Technologies LimitedAustralia
Poh Loong Soong, Co-Founder, Ternion Biosciences Pte. LtdSingapore
Ronghua Zhao, Chief Medical Officer, Virogin BiotechCanada
Younggyu Cho, Chief Technology Officer, Y BiologicsRepublic Of Korea
Mar 1912:20
Conference pass

Development of cell therapy product for pediatric orphan disease - challenges and rewards

Immunotherapy
  • Case study on current and upcoming immunotherapy and stem cell products, i.e. Cartistem, Pneumostem (orphan indication for premature babies)
  • Discussion on strategies in making immunotherapy and stem cell products more accessible for population in Asia, future plans and what’s next beyond Asia?
Mar 1912:20
Conference pass

Overview of regulatory authority inspections in EU, US, JP and CN (GCP, GVP)

Clinical trials
Mar 1912:20
Conference pass

R&D Management: Additional value enhancement through innovation

Pharma 4.0
Raphael Aswin Susilo, Vice President - Research And Development, Regulatory And Medical Affairs, Soho Global HealthIndonesia
Mar 1914:10
Conference pass
Mar 1914:10
Conference pass
Mar 1914:10
Conference pass
Mar 1914:20
Conference pass

Finding the next "niche-buster"

Immunotherapy
Mar 1914:20
Conference pass

Clinical research as tools for driving innovation

Clinical trials
Mar 1914:20
Conference pass

Making a value-outcome-based reimbursement model possible: How do we get there?

Access
Mar 1914:20
Conference pass

Building an in-house pharma AI product team: Key steps & considerations

Pharma 4.0
  • In-house vs outsource: What are the key benefits & challenges in building in-house data science projects
  • Ethics in consideration: How to make AI products more neutral and non-discriminative
  • Why data science project fails and how do we prevent it?
Mar 1914:40
Conference pass

Innovative therapeutics in immuno-oncology and inflammatory diseases

Immunotherapy
Mar 1914:40
Conference pass

Improving clinical trials with better stakeholder management

Clinical trials
Mar 1914:40
Conference pass

Renovating the R&D ecosystem for innovative health science in Japan

Pharma 4.0
Toru Seo, APAC Head, S&E, Worldwide Business Development, Chief Business Officer, PfizerJapan
Mar 1914:45
Conference pass

Biotech Pitch

Biotech Inve$t
10 minutes per company
Jang Woo Shin, Senior Principal Scientist, Yuhan R&D InstituteRepublic Of Korea
Jeff Dao, Operating Officer and Business Development Officer, HighTide TherapeuticsUnited States
Amit Kumar, Co-Founder & CEO, Biopsin Pte LtdSingapore
Mar 1914:50
Conference pass

RWE as the basis of value-based reimbursement: Applications in APAC’s pharma industry

Access
  • Overview of data-driven reimbursement process in APAC
  • Overcoming barriers to increase use of real world data
  • Improving quality of real world data
  • Standardising access and quality of RWE analytics
  • Working with payors and regulators on possible value based reimbursement model for innovative drugs and beyond
Mar 1915:00
Conference pass

Glenmark Pharmaceuticals: Advancing immunotherapy

Immunotherapy
Mahboob Rahman, President & Chief Medical Officier, Glenmark Pharmaceuticals LtdUnited States
Mar 1915:00
Conference pass
Mar 1915:00
Conference pass

Reshaping your supply chain to address supply shortage: A patient-centric approach

Pharma 4.0
Mar 1915:20
Conference pass

Immunotherapy: Opportunities and key challenges

Immunotherapy
Jerome Boyd-Kirkup, Chief Scientific Officer, Hummingbird BioscienceSingapore
Mar 1915:20
Conference pass

Paediatric subject recruitment: A cross industry perspective & future trends

Clinical trials
Mar 1916:20
Conference pass

Leveraging larger capital pools: Let’s talk listings & capital markets

Biotech Inve$t
  • Global capital markets and opportunities
  • Biotech market readiness in APAC public listing
  • Hong Kong- the next Asia biotech capital destination?
Keita Maeda, Deputy Director of Bio-Industry Division, Ministry of Economy Trade and Industry JapanJapan
Abraham Cinta, Chief Executive Officer, ARC CapitalSingapore
Mar 1916:40
Conference pass

Beyond prevention: Latest cancer vaccine developments in Asia

Immunotherapy
Mar 1916:40
Conference pass

AI in real life: How biomarkers, genomics and real-world data are changing clinical research

Clinical trials
Ross Rothmeier, Vice President, Tech Solutions, Medidata SolutionsUnited States
Mar 1916:40
Conference pass

Providing affordable access to patients in developing countries and underserved communities

Access
Mar 1916:40
Conference pass

PANEL: Igniting and fostering innovation through collaboration

Pharma 4.0
Hosted by J&J Innovation
Moderator: Giridhar Sathiamoorthy, Director, Business Operations & Project Management, Johnson & Johnson Pte LtdSingapore
Damian O'Connell, CEO Experimental Drug Development Centre, A Star - Agency For Science Technology And ResearchSingapore
Howard Califano, Director, SMART Innovation Centre, Singapore-MIT Alliance for Research and TechnologySingapore
Shridhar Gopal, Head Business Development, International, JEM&A, AbbVieUnited States
Mar 1917:00
Conference pass

Gastric and breast cancer vaccines: Case study and latest findings

Immunotherapy
Mar 1917:00
Conference pass

Innovating clinical trials with digital platforms: A cross industry case study

Clinical trials
Mar 1917:00
Conference pass

Cost management & innovative pricing strategies in high value disease management (topic to be confirmed)

Access
Mar 1917:10
Conference pass

Biotech Pitch

Biotech Inve$t
10 minutes per company
Dong-Hun Woo, COO/CTO, NexelRepublic Of Korea
Nir Arbel, Co-Founder And Chief Executive Officer, CarmentixSingapore
Yi-Chun Maria Chen, Director Of Business Development, Immunwork Inc.Taiwan
Mar 1917:20
Conference pass

Leveraging digital platforms and Electronic Medical Record (EMR) to improve patient experience and clinical trials subject recruitment

Clinical trials
Mar 1917:20
Conference pass

Technology transfer and Product Development Partnerships (PDPs) in making vaccines affordable

Access
Dr Sushant Sahastrabuddhe, Director, Enteric Fever, International Vaccine InstituteRepublic Of Korea
Mar 1917:20
Conference pass

Breaking the boundary of traditional B2B partnership: Next generation pharma-PE/VC model

Pharma 4.0

Create your personal agenda –check the favourite icon

Mar 2009:00
Conference pass

Disrupt before being disrupted: Using digital tech to connect to previously uneconomic chronic disease customers

Keynotes
Insurance is a tricky part of healthcare business. Increased healthcare costs lead to a higher profit for pharma and provider companies but burdens the government budget and hurts the insurance business. Since taking care of a chronic patient is a lifelong commitment, the availability of insurance to cover this essential treatment is often expensive and uneconomical. Join Nadia Suttikulpanich, Head of the Fuchsia Innovation Center, part of Muang Thai Life Assurance, Thailand as she shares how they are adopting digital tech to pilot chronic disease cover to provide for patients in need while keeping their insurance business profitable.
Nadia Suttikulpanich, Head Of Fuchsia Innovation Center For Muang Thai Life Assurance, Muang Thai Life Assurance Public CompanyThailand
Mar 2009:20
Conference pass

The path to personalised medicine: Key developments

Keynotes
Everyone knows the potential benefits of personalised medicine, but how do we get there? Finding and better defining disease through biomarkers and more accurate diagnostics. Targeted therapeutics to leverage new and emerging diagnostic capabilities. Personalized Medicine to Real-Time Medicine. How to drive success across industry and clinical implementation in an economic manner. This presentation discusses various strategies and key considerations to drive the symbiosis between academia, industry and clinical medicine to drive vastly improved patient outcomes.
Mar 2009:40
Conference pass

Pharma 4:0 Digital disruption: New players, new opportunities

Keynotes
Andreas Koester, Global Head & VP, Janssen Clinical Innovation, Johnson & JohnsonUnited States
Matt Cooper, Business Development And Research Director, NIHR Clinical Research NetworkUnited Kingdom
Mar 2010:20
Conference pass

Attracting VC capital: What are investors looking for from early stage Asian biotechs?

Biotech Inve$t
Moderator: Mayank Gurnani, Associate Director, Industry Liaison Office, National University of SingaporeSingapore
Hsien-Hui Tong, Head, Venture Investing, SGInnovateSingapore
Mar 2010:21
Conference pass

Table 1 Working with clinical outsourcing partners: Risk management and prevention

Keynotes
Mar 2010:21
Conference pass

Table 2 Fostering commercial partnerships to tap on emerging APAC markets

Keynotes
Mar 2010:21
Conference pass

Table 3 Regulatory collaboration and opportunities in more efficient drug development

Keynotes
Mar 2010:21
Conference pass

Table 4 - Enhancing patient engagement in clinical trials

Keynotes
Mar 2010:21
Conference pass

Table 5 - Futureproofing the workforce and leveraging the sharing economy in your business

Keynotes
Mar 2010:21
Conference pass

Table 6 - Precision to personalised medecine: How do we get there?

Keynotes
Mar 2010:21
Conference pass

Table 7 - Outsourcing your injectable: Benefit from an experienced CDMO partner

Keynotes
Mar 2011:00
Conference pass

Funding risk & return strategies: Investor & investee perspectives

Biotech Inve$t
Anthony Desir, Director, MoexaHong Kong
Mar 2011:20
Conference pass

Biotech Pitch

Biotech Inve$t
10 minutes per company
Don Lee, Manager, SCM LifescienceRepublic Of Korea
Sungjae Ha, Chief Technology Officer, FemtobiomedRepublic Of Korea
Mar 2011:40
Conference pass

Overview: Targeted therapies in enabling precision medicine

Immunotherapy
  • Combination studies in Asia-latest updates
  • Deciding between targeted oncology therapies vs I-O, key considerations
  • Key actions transitioning from followers to leaders in targeted therapies
Mar 2011:40
Conference pass
Mar 2011:40
Conference pass

Convergence, harmonisation and collaboration: The evolution of Asia’s pharma regulatory landscape

Regulatory Affairs
Mar 2011:40
Conference pass

Beyond the pill, beyond the scalpel: New approaches to medicine in the realm of the digital and electronic

Pharma 4.0
Mar 2012:00
Conference pass

Clinical Development of CAR-T, Stem Cells and other Cellular Therapy Products

Clinical trials
Mar 2012:00
Conference pass

Challenges, opportunities and partnerships in the ASEAN pharma industry: A regulatory perspective

Regulatory Affairs
Kum Cheun Wong, Head Asia Pacific Policy And Liaison, Drug Regulatory Affairs, Novartis Asia PacificSingapore
Mar 2012:00
Conference pass

Innovating with the patient for the patient: Using data for patient engagement in clinical trials

Pharma 4.0
Andreas Koester, Global Head & VP, Janssen Clinical Innovation, Johnson & JohnsonUnited States
Mar 2012:20
Conference pass

Development of next generation tumor immunotherapy

Immunotherapy
Mar 2012:20
Conference pass

Gearing up for a clinic with CRISPR technology: New strategies

Clinical trials
Mar 2012:20
Conference pass

Digital intervention in streamlining regulatory publishing & submission activities

Regulatory Affairs
Handsome Ji, Apac Publishing Lead, Pfizer ChinaChina
Mar 2012:20
Conference pass

Harnessing clinically validated AI to optimise drug development and digital medicine

Pharma 4.0
Dean Ho, Co-Founder, KYAN TherapeuticsUnited States
Mar 2012:40
Conference pass

Next generation targeted agents and immuno-oncology therapies

Immunotherapy
Mar 2012:40
Conference pass

East meets West: A case study in clinical development

Clinical trials
Judith Walker, Chief Medical Officer, CerecinSingapore
Mar 2012:40
Conference pass

Stakeholder management in regulatory affairs: A case study

Regulatory Affairs
Mar 2012:40
Conference pass
Mar 2013:00
Conference pass

The Greater China Opportunity: Capital raising & partnerships

Biotech Inve$t
Mar 2013:50
Conference pass

Biotech Pitch

Biotech Inve$t
10 minutes per company
Hoon Seong, Deputy Manager, Genome & CompanyRepublic Of Korea
Alexander Kort, Senior Vice President Corporate Development, Themis Bioscience GmbHAustria
Andreas Schmidt, Chief Executive Officer, ProteonaSingapore
Kiyoshi Takayama, President, N.B. Health Laboratory Co LtdJapan
Ignacio Asial, Founder & CEO, DOTBIOSingapore
Wei Jiang Goh, Co-Founder & CEO, Craft HealthSingapore
Mar 2014:30
Conference pass

The future of next generation combination therapies

Immunotherapy
Mar 2014:30
Conference pass

Clinical trial capacity related to MRCT in Taiwan

Clinical trials
Mar 2014:30
Conference pass

Expedited review pathways in North East Asia and what it means for APAC stakeholders

Regulatory Affairs
  • Priority review and reform for new product launches in China
  • Latest updates on Good registration management (GRM) and approval pathways in Japan, Korea, Taiwan
  • Opportunities to expand to greater Asia and lessons for the rest of Asia
Moderator: Jeff Weisel, Director, Life Sciences & Healthcare Transaction Advisory, EYSingapore
Handsome Ji, Apac Publishing Lead, Pfizer ChinaChina
Finny Liu, Apac Regional Regulatory Policy Lead, RocheSingapore
Mar 2014:30
Conference pass

Consumer health informatics: Digital platforms for better patient engagement

Pharma 4.0
Adam Chee, Founder & Chief Advocacy Officer, BinaryHealthCareSingapore
Mar 2014:50
Conference pass

Next generation combination therapies with bioconjugation

Immunotherapy
Gang Qin, Chief Executive Officer, GeneQuantum Healthcare SuzhouChina
Mar 2014:50
Conference pass

GCP and safety guidelines for biosimilars products

Clinical trials
Mar 2014:50
Conference pass

Remote patient management solutions for better engagement

Pharma 4.0
Mar 2015:10
Conference pass

Beyond T-cell I-O: Antiviral immunotherapy

Immunotherapy
Mar 2015:10
Conference pass

Virtual Reality for patient care and engagement

Pharma 4.0
Mar 2015:30
Conference pass

Applying precision and immunotherapy to prevent infectious diseases

Immunotherapy
Alexander Kort, Senior Vice President Corporate Development, Themis Bioscience GmbHAustria
Mar 2015:30
Conference pass

The role of pharmacovigilance in ensuring health product safety

Regulatory Affairs
Mar 2015:30
Conference pass

Using real world data in digital intervention

Pharma 4.0
Teng Yan Yau, Chief Medical Officer, HolmuskSingapore
Mar 2015:30
Conference pass

Biotech Pitch

Biotech Inve$t
10 minutes per company
Mar 2015:50
Conference pass

Regulatory compliance in biologic products comparability following technology transfer

Regulatory Affairs
Mar 2015:50
Conference pass

Choosing the right business model for digital therapeutics

Pharma 4.0
Bechara Saab, Chief Executive Officer and Chief Scientist, Mobio InteractiveChina
last published: 18/Mar/19 14:05 GMT

 

 

DOWNLOAD PROSPECTUS

 

 

For speaking, sponsorship and exhibition opportunities contact jonathan.mottram@terrapinn.com
Tel: +65 6322 2738